<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763018</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-OO8</org_study_id>
    <nct_id>NCT04763018</nct_id>
  </id_info>
  <brief_title>Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users</brief_title>
  <official_title>A Randomized Sham Controlled Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympic Ophthalmics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olympic Ophthalmics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two study arms - sham and treatment; There will be a cross over of the sham group to the&#xD;
      treatment group at day 15.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market study. The active device will be the FDA cleared device used within its&#xD;
      labeling. The sham group will receive an iTEAR device which looks identical to and makes&#xD;
      noise similar to a fully functional iTEAR device but has a tip that does not vibrate. All&#xD;
      subjects in the sham group will crossover to the treatment group after 2 two weeks and all&#xD;
      patients will continue to 30 days.&#xD;
&#xD;
      The study will be conducted at up to 5 sites in the United States. It will enroll 30 subjects&#xD;
      for 30 days.&#xD;
&#xD;
      This is a double-masked study with 10 subjects receiving sham and 20 subjects receiving&#xD;
      treatment. The subjects and the examining investigators are masked to treatment until the&#xD;
      crossover.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 17, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Day 14-30, all subjects receive therapy device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Sham device produces noise but no stimulation energy. Assessor does not know which device the subject received. The subject does not know which device he or she received</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Meibomian Gland change in expressibility</measure>
    <time_frame>14 days</time_frame>
    <description>Change in gland expression from meibomian glands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>14 days</time_frame>
    <description>Change in Staining of cornea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal tear output</measure>
    <time_frame>14 days</time_frame>
    <description>Change in the basal output of tears</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of Events which prevent device usage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Visual Display Users With Previously Undiagnosed Dry Eye</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive a function iTEAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This arm will receive sham treatment device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTEAR100</intervention_name>
    <description>Neurostimulation external nasal nerve to stimulate tear production</description>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 6hrs visual display terminal&#xD;
&#xD;
          -  OSDI &gt; 13&#xD;
&#xD;
          -  One of: SChirmer &lt; 10, One quadrant staining &gt; 2, or Meibomian Gland expression &lt;12&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opinion of investigator that subject not be in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael gertner, MD</last_name>
    <phone>650-283-9388</phone>
    <email>mgertner@oo-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fishman Vision</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All results will be shared at conclusion of last follow up visit</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>December 2021</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

